Intravitreal aflibercept 2 mg prefilled syringes are linked to larger delivery volumes and greater immediate IOP elevation.

Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W. SAN FRANCISCO ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...

Japan MHLW grants marketing authorization to Bayer’s Eylea 8 mg to treat patients with macular edema following RVO: Berlin Tuesday, March 24, 2026, 13:00 Hrs [IST] The Ministry ...

Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring ...

Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to ...

Eyepoint Pharma () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing ...

When discussing how long Eylea stays in your system, it’s important to distinguish between how long the drug remains in your eye versus your bloodstream. According to the drug’s prescribing ...

Faricimab showed better control of PED, SHRM, and HRF compared to aflibercept in treatment-naïve nAMD and PCV patients. Both faricimab and aflibercept improved BCVA and reduced CMT, but faricimab ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...